LifeMD 10-Q: Q3 Revenue Falls 7% to $44.6M, Prior Financials Revised for Revenue Errors
LFMD is trading near its 52-week low of $1.6 (0.6% above the low) on elevated volume (2.0× avg).
Summary
LifeMD's Q3 10-Q shows revenue down 7% to $44.6 million and a $20.6 million nine-month loss, alongside a revision of 2024-2026 financials for revenue-recognition errors and four unremediated material weaknesses.
Key Events · Earnings and Guidance · LFMD
-
Q3 Revenue Falls 7% to $44.6M
Telehealth revenue, net was $44,625,086 for the three months ended September 30, 2026 versus $47,727,942 a year earlier, driven by a $3.2 million drop in telehealth product revenue on weaker online sales demand.
-
Prior Financials Revised for Revenue Errors
The company is revising 2024, 2025 and 2026 interim statements for agent-vs-principal revenue recognition errors; the December 31, 2025 balance sheet takes a $6,819,395 hit to receivables and a $4,825,441 increase in accumulated deficit.
-
Four Material Weaknesses Unremediated
Management concluded disclosure controls were not effective as of September 30, 2026, citing unremediated weaknesses in revenue recognition, segregation of duties, information produced by the entity, and IT general controls.
-
Cash Down to $21.9M, Negative Working Capital
Cash fell to $21,921,769 from $36,786,318 at December 31, 2025, and working capital swung to a $12,443,474 deficit from a $5,432,659 surplus, with nine-month operating cash use of $7,430,657.
Analysis · LFMD · Industrial Applications And Services
The headline numbers were pre-released on November 12, but the 10-Q is where the damage is quantified. LifeMD is restating revenue recognition across 2024, 2025 and the first half of 2026 because it booked certain third-party pharmacy arrangements net when it should have been gross — the December 31, 2025 balance sheet loses $6.8 million of receivables and gains $4.8 million of accumulated deficit. On top of that, four material weaknesses in internal control remain unremediated, including the very revenue-recognition control that caused the revision. Cash dropped to $21.9 million from $36.8 million at year-end and working capital is now negative $12.4 million, which is why the company replaced its undrawn Citizens revolver with a $12.5 million Avenue term loan carrying an 11.5% floor and a $150 million trailing-revenue covenant starting with the December 31, 2026 quarter. Nine-month losses from continuing operations widened to $20.6 million from $10.0 million. The accounting credibility problem, not the revenue miss, is what matters here.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFMD was trading at $1.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $1.60 to $5.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.